Aspirin Named 8th World Wonder by Majority of...(rapyfor prevention of heart attack a mov...),Health

Date:8/19/2007

rapy for prevention of heart attack, a move that Dr. Roizen estimates could potentially prevent tens of thousands of heart attacks each year. Most recently, it has been estimated that if physicians advised all high-risk adults to start regular aspirin therapy, more than 80,000 lives could be saved each year.

EDITOR NOTE: to view the online press kit please visit: http://onekit.enr- corp.com/1002215/index.html.

About the Wonders Survey

Opinion Research Corporation conducted a survey on current wonders from March 30, 2007 through April 2, 2007 among 1,038 American consumers via telephone. The margin of error is +/- 3%.

About Bayer Consumer Care

The Consumer Care Division of Bayer HealthCare LLC, is headquartered in Morristown, N.J. Bayer's Consumer Care Division is among the largest marketers of over-the-counter medications and nutritional supplements in the world. Some of the most trusted and recognizable brands in the world today come from the Bayer portfolio of products. These include Bayer(R) Aspirin, Aleve(R), Alka-Seltzer Plus(R), Bactine(R), RID(R), Phillips'(R) Milk of Magnesia, Midol(R), Alka-Seltzer(R), One-A-Day(R) and Flintstones(TM) vitamins.

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the health care and medical products industry based in Leverkusen/Germany. In 2006, the Bayer HealthCare subgroup generated sales amounting to some 11.7 billion Euro. The company combines the global activities of the divisions Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals. Since January 1, 2006 the new Pharmaceutical Division consists of the former Biological Products and Pharmaceutical Division and now comprises three business units: Hematology/Cardiology, Oncology and Primary Care. Bayer HealthCare's aim is to discover and manufacture innovative products that will improve human and animal health worldwide. The products
'/>"/>

SOURCE Bayer HealthCare Copyright©2007 PR Newswire.

1 GOOD

Page: 1 2 3 4
Related medicine technology :

1. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
2. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting
5. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
6. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
7. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
8. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
9. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
10. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
11. Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting